References
- Smith DJ, Lapedes AS, de Jong JC et al. Mapping the antigenic and genetic evolution of influenza virus. Science305(5682), 371–376 (2004).
- Hensley SE, Das SR, Bailey AL et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science326(5953), 734–736 (2009).
- Kilbourne ED, Johansson BE, Grajower B. Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc. Natl Acad. Sci. USA87(2), 786–790 (1990).
- Hayden F. Developing new antiviral agents for influenza treatment: what does the future hold? Clin. Infect. Dis.48(Suppl. 1), S3–S13 (2009).
- Liu C, Eichelberger MC, Compans RW, Air GM. Influenza type A virus neuraminidase does not play a role in viral entry, replication, assembly, or budding. J. Virol.69(2), 1099–1106 (1995).
- Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J. Virol.78(22), 12665–12667 (2004).
- Palese P, Tobita K, Ueda M, Compans RW. Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology61(2), 397–410 (1974).
- Gubareva LV, Kaiser L, Matrosovich MN, Soo-Hoo Y, Hayden FG. Selection of influenza virus mutants in experimentally infected volunteers treated with oseltamivir. J. Infect. Dis.183(4), 523–531 (2001).
- Collins PJ, Haire LF, Lin YP et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature453(7199), 1258–1261 (2008).
- Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A/H1N1 neuraminidase active site following oseltamivir phosphate treatment leave virus severely compromised both in vitro and in vivo. Antiviral Res.55(2), 307–317 (2002).
- Abed Y, Goyette N, Boivin G. A reverse genetics study of resistance to neuraminidase inhibitors in an influenza A/H1N1 virus. Antivir. Ther.9(4), 577–581 (2004).
- Herlocher ML, Truscon R, Elias S et al. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. J. Infect. Dis.190(9), 1627–1630 (2004).
- Moscona A. Global transmission of oseltamivir-resistant influenza. N. Engl. J. Med.360(10), 953–956 (2009).
- Bloom JD, Gong LI, Baltimore D. Permissive secondary mutations enable the evolution of influenza oseltamivir resistance. Science328(5983), 1272–1275 (2010).
- Hensley SE, Das SR, Gibbs JS et al. Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PLoS ONE6(2), e15190 (2011).
- Kramarz P, Monnet D, Nicoll A, Yilmaz C, Ciancio B. Use of oseltamivir in 12 European countries between 2002 and 2007 – lack of association with the appearance of oseltamivir-resistant influenza A(H1N1) viruses. Euro Surveill.14(5), pii: 19112 (2009).
- Wang X, Minasov G, Shoichet BK. Evolution of an antibiotic resistance enzyme constrained by stability and activity trade-offs. J. Mol. Biol.320(1), 85–95 (2002).
- Schrag SJ, Perrot V, Levin BR. Adaptation to the fitness costs of antibiotic resistance in Escherichia coli. Proc. Biol. Sci.264(1386), 1287–1291 (1997).
- Kelleher AD, Long C, Holmes EC et al. Clustered mutations in HIV-1 gag are consistently required for escape from HLA-B27-restricted cytotoxic T lymphocyte responses. J. Exp. Med.193(3), 375–386 (2001).